In an interview with Targeted Oncology, David Sallman, MD, of Moffitt Cancer Center, addresses the nuanced decision-making ...
Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...
With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing ...
Chemotherapy-induced myelosuppression (CIM) remains one of the most significant and underappreciated barriers to delivering ...
AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral ...
In topline results from the phase 3 SENTRY trial, the combination of selinexor and ruxolitinib achieved a statistically ...
WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...
Richardson, MD, explains the distinct potential roles and combinations including iberdomide and mezigdomide in multiple myeloma treatment. Paul G. Richardson, MD, director of Clinical Research and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results